• SENSEX
    NIFTY 50
Healthcare

Serum Institute of India seeks DCGI permission for phase 2/3 clinical trials of Oxford's COVID 'vaccine'

Updated : July 25, 2020 07:34 PM IST

The sources told PTI that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials of 'Covidshield'.
The firm plans to start phase 2 and 3 human trials in India in August.
Serum Institute of India seeks DCGI permission for phase 2/3 clinical trials of Oxford's COVID 'vaccine'

You May Also Like

Live TV
Advertisement